Opdivo is a brand name for the drug nivolumab, which is a type of immunotherapy used in the treatment of various types of cancer. According to the provided sources, Opdivo's patent is set to expire at different times depending on the country and the specific patent.

The first source, DrugPatentWatch, provides information on Opdivo's patent expiration in different countries. It states that the patent for Opdivo expired in Europe on October 10, 2020, and it will expire in the United States on July 24, 2026. However, it is important to note that this information is subject to change, and it is always best to consult official sources or legal experts for the most up-to-date information.

The second source, FiercePharma, mentions that Opdivo's patent expiration is expected to occur in 2026. This aligns with the information provided by DrugPatentWatch regarding the expiration date in the United States.

The third source, The Motley Fool, discusses the potential impact of new blockbuster drugs on Bristol-Myers Squibb, the company that manufactures Opdivo. While it does not specifically mention Opdivo's patent expiration date, it provides insights into the company's future prospects and potential new drugs that could fill the revenue gap left by patent expirations.

In summary, Opdivo's patent has already expired in Europe and is set to expire in the United States on July 24, 2026, according to the provided sources. However, it is important to verify this information with official sources or legal experts for the most accurate and up-to-date information.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/biologics/tradename/OPDIVO
[2] FiercePharma: https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade
[3] The Motley Fool: https://www.fool.com/investing/2022/07/28/these-new-blockbusters-could-fill-bristol-myers-sq/